Drug prophylaxis evidence-based regimens for venous thromboembolism after joint replacement

FENG Xiaowei; GUO Na; WANG Baozhen; CHENG Jie; TANG Yuchen; QI Jun; DONG Zhiqiang

doi:10.6039/j.issn.1001-0408.2024.22.17

您当前的位置：

首页 >

文章列表页 >

Drug prophylaxis evidence-based regimens for venous thromboembolism after joint replacement

更新时间：2024-11-26

- Drug prophylaxis evidence-based regimens for venous thromboembolism after joint replacement
- ZHONGGUO YAOFANG Vol. 35, Issue 22, Pages: 2799-2807(2024)
- 作者机构：
  
  1.内蒙古科技大学包头医学院药学院，内蒙古包头　014040
  2.内蒙古科技大学包头医学院第一附属医院药物临床研究室，内蒙古包头　014040
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.22.17
  CLC： R973+.2
- Published：30 November 2024，
  
  Received：10 May 2024，
  
  Revised：12 September 2024，
- 稿件说明：
移动端阅览
冯潇纬,郭娜,王宝珍等.关节置换术后静脉血栓栓塞症的药物预防循证方案 ^Δ[J].中国药房,2024,35(22):2799-2807.

FENG Xiaowei,GUO Na,WANG Baozhen,et al.Drug prophylaxis evidence-based regimens for venous thromboembolism after joint replacement[J].ZHONGGUO YAOFANG,2024,35(22):2799-2807.
冯潇纬,郭娜,王宝珍等.关节置换术后静脉血栓栓塞症的药物预防循证方案 ^Δ[J].中国药房,2024,35(22):2799-2807. DOI： 10.6039/j.issn.1001-0408.2024.22.17.

FENG Xiaowei,GUO Na,WANG Baozhen,et al.Drug prophylaxis evidence-based regimens for venous thromboembolism after joint replacement[J].ZHONGGUO YAOFANG,2024,35(22):2799-2807. DOI： 10.6039/j.issn.1001-0408.2024.22.17.

摘要

目的

梳理人工关节置换术后成人患者发生静脉血栓栓塞症（VTE）的药物预防方案，为临床提供依据。

方法

按照“6S”模型检索英国国家卫生与临床优化研究所（NICE）、苏格兰校际指南网络（SIGN）、国际指南协作网（GIN）、美国国立实践技术指南库（NGC）、PubMed、Embase、中国知网、万方数据、中国生物医学文献服务系统和相关官方网站，纳入研究预防人工关节置换术后成人患者VTE的指南、专家共识、系统评价、随机对照试验和队列研究，检索时限为建库起至2023年12月。选出符合纳入标准的文献，由2名研究人员独立完成文献质量评价，并采用乔安娜布里格斯研究所（JBI）证据预分级及证据推荐级别系统（2014版）对其进行证据评定。

结果

共纳入36篇文献，涵盖风险评估、评估后预防措施、药物选择、药物使用方法、药物预防时间、药物预防观察要点、药物预防禁忌证、出血应对措施、健康教育9个方面，总结形成37条人工关节置换术后VTE的药物预防证据。

结论

本研究总结出的人工关节置换术后VTE的药物预防证据较为全面，具有一定的科学性和实用性，可为临床药师提供科学的围术期VTE预防管理循证依据。

Abstract

OBJECTIVE

To sort out drug prophylaxis regimens for venous thromboembolism （VTE） in adult patients after artificial joint replacement， and provide a basis for clinic.

METHODS

Databases and related official websites were searched according to the “6S” model， including the National Institute for Health and Clinical Excellence （NICE）， the Scottish Intercollegiate Guidelines Network （SIGN）， the Guidelines International Network （GIN）， the National Guidelines Clearinghouse （NGC）， PubMed， Embase， CNKI， Wanfang database and SinoMed， to search for guidelines， expert consensuses， systematic evaluations， randomized controlled trials， and cohort studies about preventing VTE in adult patients after artificial joint replacement from the inception until December 2023. Literature that met the inclusion criteria were selected， and the quality evaluation of the literature was completed by 2 researchers independently； the evidence rating was performed by using the Joanna Briggs Institute （JBI） evidence pre-classification and evidence rank system （2014 edition）.

RESULTS

A total of 36 articles were included in the study， which were categorized into 9 areas of risk assessment， post-assessment prophylaxis， medication selection， medication method， duration of medication prophylaxis， medication prophylaxis observation points， contraindications to drug prophylaxis， response to bleeding， and health education， which were summarized to form 37 pieces of evidence on the pharmacological prophylaxis for postoperative VTE in patients who underwent artificial joint replacement.

CONCLUSIONS

The evidence of drug prophylaxis for postoperative VTE in patients who underwent artificial joint replacement summarized in this study is comprehensive， with certain scientific reference and practicality， which can provide clinical pharmacists with a scientific evidence-based basis for perioperative VTE prophylaxis management.

关键词

静脉血栓栓塞症人工关节置换术药物预防循证药学

Keywords

artificial joint replacementdrug prophylaxisevidence-based pharmacy

references

LAPIDUS L J，PONZER S，PETTERSSON H，et al. Symptomatic venous thromboembolism and mortality in orthopaedic surgery：an observational study of 45 968 consecutive procedures[J]. BMC Musculoskelet Disord，2013，14：177.

中华医学会骨科学分会. 中国骨科大手术静脉血栓栓塞症预防指南[J]. 中华骨科杂志，2016（2）：65-71.

Chinese Orthopaedic Association. Guidelines for the prevention of venous thromboembolism in major orthopedic surgery in China[J]. Chin J Orthop，2016（2）：65-71.

IBRAHIM M S，TWAIJ H，GIEBALY D E，et al. Enhanced recovery in total hip replacement：a clinical review[J]. Bone Joint J，2013，95-B（12）：1587-1594.

National Institute for Health and Care Excellence. Venous thromboembolism in over16s：reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism[EB/OL]. （2019-08-13） [2023-12-01]. https：//www.nice.org.uk/guidence/ng89https://www.nice.org.uk/guidence/ng89.

韩凤昭，李振知，杨文华. 临床药师参与骨科临床路径中抗凝治疗的探索与思考[J]. 中南药学，2017，15（8）：1164-1167.

HAN F Z，LI Z Z，YANG W H. Role of clinical pharmacists in anticoagulant treatment in orthopedic clinical pathways[J]. Cent South Pharm，2017，15（8）：1164-1167.

ZHAI Z G，KAN Q C，LI W M，et al. VTE risk profiles and prophylaxis in medical and surgical inpatients：the identification of Chinese hospitalized patients’ risk profile for venous thromboembolism （DissolVE-2）：a cross-sectional study[J]. Chest，2019，155（1）：114-122.

The AGREE Next Steps Consortium. AGREE Ⅱ translations：Chinese[EB/OL]. （2009-11-12） [2023-12-01]. https：//www.agreetrust.org/resource-centre/https://www.agreetrust.org/resource-centre/.

胡雁，郝玉芳. 循证护理学[M]. 2版. 北京：人民卫生出版社，2018：91-93.

HU Y，HAO Y F. Evidence-based nursing[M]. 2nd edition. Beijing：People’s Medical Publishing House，2018：91-93.

曾宪涛，黄伟，田国祥. Meta分析系列之九：Meta分析的质量评价工具[J]. 中国循证心血管医学杂志，2013，5（1）：3-5.

ZENG X T，HUANG W，TIAN G X. Meta-analysis series 9：quality evaluation tool of meta-analysis[J]. Chin J Evid Based Cardiovasc Med，2013，5（1）：3-5.

MARGULIS A V，PLADEVALL M，RIERA-GUARDIA N，et al. Quality assessment of observational studies in a drug-safety systematic review，comparison of two tools：the Newcastle-Ottawa scale and the RTI item bank[J]. Clin Epidemiol，2014，6：359-368.

JING W Z，ZHAO S Y，LIU J，et al. ABO blood groups and hepatitis B virus infection：a systematic review and meta-analysis[J]. BMJ Open，2020，10（1）：e034114.

曾宪涛，包翠萍，曹世义，等. Meta分析系列之三：随机对照试验的质量评价工具[J]. 中国循证心血管医学杂志，2012，4（3）：183-185.

ZENG X T，BAO C P，CAO S Y，et al. Meta-analysis series 3：quality evaluation tool for randomized controlled trials[J]. Chin J Evid Based Cardiovasc Med，2012，4（3）：183-185.

王春青，胡雁. JBI证据预分级及证据推荐级别系统：2014版[J]. 护士进修杂志，2015，30（11）：964-967.

WANG C Q，HU Y. JBI evidence pre-classification and evidence rank system：2014 edition[J]. J Nurses Train，2015，30（11）：964-967.

中华医学会呼吸病学分会肺栓塞与肺血管病学组，中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会，全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志，2018，98（14）：1060-1087.

Pulmonary Embolism and Pulmonary Vascular Disease Group of the Respiratory Disease Branch of the Chinese Medical Association，Working Committee on Pulmonary Embolism and Pulmonary Vascular Disease of the Respiratory Physicians Branch of the Chinese Medical Doctor Association，National Collaborative Group for Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular Disease. Guidelines on the diagnosis，treatment and prevention of pulmonary thromboembolism[J]. Natl Med J China，2018，98（14）：1060-1087.

《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志，2018，98（36）：2861-2888.

Expert Committee on Guidelines for the Prevention and Treatment of Thrombotic Diseases in China. Guidelines for the prevention and treatment of thrombotic diseases in China[J]. Natl Med J China，2018，98（36）：2861-2888.

全国肺栓塞和深静脉血栓形成防治能力建设项目专家委员会，《医院内静脉血栓栓塞症防治质量评价与管理指南（2022版）》编写专家组. 医院内静脉血栓栓塞症防治质量评价与管理指南：2022版[J]. 中华医学杂志，2022，102（42）：3338-3348.

The National Pulmonary Embolism and Deep Venous Thrombosis Prevention and Control Capa-city Building Project Expert Committee，Expert Group Responsible for Drafting the Guidelines for Quality Evaluation and Ma-nagement of Prevention and Treatment of Venous Thromboembolism in Hospitals （2022 edition）. Guidelines for quality evaluation and management of prevention and treatment of venous thromboembolism in hospitals：2022 edition[J]. Natl Med J China，2022，102（42）：3338-3348.

王乔宇，武明芬，柳鑫，等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志，2021，37（21）：2999-3016.

WANG Q Y，WU M F，LIU X，et al. Guidelines for the selection and pharmaceutical care of anticoagulants for the prevention and treatment of venous thromboembolism in China of 2021[J]. Chin J Clin Pharmacol，2021，37（21）：2999-3016.

ENCKE A，HAAS S，KOPP I. The prophylaxis of venous thromboembolism[J]. Dtsch Arztebl Int，2016，113（31/32）：532-538.

Cardiovascular Disease Educational and Research Trust，Cyprus Cardiovascular Disease Educational and Research Trust，European Venous Forum，et al. Prevention and treatment of venous thromboembolism. International consensus statement：guidelines according to scientific evidence[J]. Int Angiol，2006，25（2）：101-161.

MONT M A，JACOBS J J，BOGGIO L N，et al. Preven-ting venous thromboembolic disease in patients under-going elective hip and knee arthroplasty[J]. J Am Acad Orthop Surg，2011，19（12）：768-776.

SCHÜNEMANN H J，CUSHMAN M，BURNETT A E，et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism：prophylaxis for hospitalized and nonhospitalized medical patients[J]. Blood Adv，2018，2（22）：3198-3225.

NEUMANN I，IZCOVICH A，AGUILAR R，et al. ASH，ABHH，ACHO，Grupo CAHT，Grupo CLAHT，SAH，SBHH，SHU，SOCHIHEM，SOMETH，Sociedad Pana-meña de Hematología，SPH，and SVH 2021 guidelines for management of venous thromboembolism in Latin America[J]. Blood Adv，2021，5（15）：3032-3046.

ANDERSON D R，MORGANO G P，BENNETT C，et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism：prevention of venous thromboembolism in surgical hospitalized patients[J]. Blood Adv，2019，3（23）：3898-3944.

Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism[EB/OL]. （2010-10-10） [2023-12-01]. http：//www.sign.ac.ukhttp://www.sign.ac.uk.

赵纪春，邱贵兴，裴福兴，等. 骨科大手术加速康复围手术期静脉血栓栓塞症防治专家共识[J]. 中华骨与关节外科杂志，2022，15（10）：754-762.

ZHAO J C，QIU G X，PEI F X，et al. Expert consensus on the prevention and treatment of perioperative venous thromboembolism in major orthopaedic surgery in enhanced recovery after surgery program[J]. Chin J Bone Jt Surg，2022，15（10）：754-762.

TOMKOWSKI W，KUCA P，URBANEK T，et al. Venous thromboembolism：recommendations on the prevention，diagnostic approach and management：the 2017 Polish consensus statement[J]. Acta Angiol，2017，23：35-71.

杨婕，温华，马冰，等. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践杂志，2018，36（6）：541-546.

YANG J，WEN H，MA B，et al. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty：a net meta-analysis[J]. J Pharm Pract，2018，36（6）：541-546.

HAYKAL T，KHEIRI B，ZAYED Y，et al. Aspirin for venous thromboembolism prophylaxis after hip or knee arthroplasty：an updated meta-analysis of randomized controlled trials[J]. J Orthop，2019，16（4）：312-319.

MATHARU G S，KUNUTSOR S K，JUDGE A，et al. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement：a systematic review and meta-analysis of randomized clinical trials[J]. JAMA Intern Med，2020，180（3）：376-384.

KAPOOR A，ELLIS A，SHAFFER N，et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement：a network meta-analysis[J]. J Thromb Haemost，2017，15（2）：284-294.

HUR M，PARK S K，KOO C H，et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty[J]. Acta Orthop，2017，88（6）：634-641.

魏志辉，张铭华，赵波，等. 不同剂量利伐沙班与依诺肝素预防全髋关节置换后静脉血栓形成：安全及有效性的Meta分析[J]. 中国组织工程研究，2016，20（53）：8022-8031.

WEI Z H，ZHANG M H，ZHAO B，et al. Different doses of rivaroxaban versus enoxaparin for prevention of venous thromboembolism after total hip arthroplasty：a meta-analysis of safety and efficacy[J]. Chin J Tissue Eng Res，2016，20（53）：8022-8031.

LIU J C，ZHAO J L，YAN Y，et al. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement：a systematic review and meta-analysis[J]. Medicine，2019，98（9）：e14539.

GAO J H，CHU X C，WANG L L，et al. Effects of diffe-rent anticoagulant drugs on the prevention of complications in patients after arthroplasty：a network meta-analysis[J]. Medicine，2017，96（40）：e8059.

XU J，CHANG D，CHUI J，et al. The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty：a meta-analysis[J]. J Orthop，2022，30：1-6.

HUANG Z H，XU X R，XU D，et al. Efficacy of 11 anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty：a systematic review and network meta-analysis[J]. Medicine，2023，102（2）：e32635.

PATHAK R，GIRI S，KARMACHARYA P，et al. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients[J]. Blood Coagul Fibrinolysis，2015，26（8）：934-939.

YI Y H，GONG S，GONG T L，et al. New oral anticoagulants for venous thromboembolism prophylaxis in total hip and knee arthroplasty：a systematic review and network meta-analysis[J]. Front Pharmacol，2021，12：775126.

FENG W L，WANG X P，HUANG D Q，et al. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty：a systematic review and a network meta-analysis[J]. Pharmacol Res，2021，166：105438.

HU B S，JIANG L X，TANG H X，et al. Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery：a meta-analysis[J]. J Orthop Surg Res，2021，16（1）：135.

MENG J H，LIU W J，XIAO Y F，et al. The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty：a meta-analysis of randomized controlled trials[J]. Int J Surg，2023，109（11）：3648-3655.

HOWARD T A，JUDD C S，SNOWDEN G T，et al. Incidence and risk factors associated with venous thromboembolism following primary total hip arthroplasty in low-risk patients when using aspirin for prophylaxis[J]. Hip Int，2022，32（5）：562-567.

FUJI T，NAKAMURA M，TAKEUCHI M. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery：results from 2 randomized，placebo-controlled，double-blind studies[J]. Clin Appl Thromb Hemost，2014，20（2）：199-211.

LASSEN M R，BORRIS L C，JENSEN H P，et al. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin （tinzaparin） in elective hip arthroplasty[J]. Clin Appl Thromb Hemost，2000，6（1）：53-57.

FUJI T，FUJITA S，TACHIBANA S，et al. A dose-ranging study evaluating the oral factor Ⅹa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty[J]. J Thromb Haemost，2010，8（11）：2458-2468.

TURPIE A G，BAUER K A，DAVIDSON B L，et al. A randomized evaluation of betrixaban，an oral factor Ⅹa inhibitor，for prevention of thromboembolic events after total knee replacement （EXPERT）[J]. Thromb Haemost，2009，101（1）：68-76.

江肃非. 阿哌沙班与依诺肝素预防老年糖尿病患者髋关节置换术后深静脉血栓形成的对比研究[J]. 血栓与止血学，2013，19（4）：150-152.

JIANG S F. The comparative study of apixaban and enoxaparin to prevent elderly diabetic patients with hip arthroplasty postoperative deep venous thrombosis[J]. Chin J Thromb Hemostasis，2013，19（4）：150-152.

卢克鹏，刘彩虹，毕莹. 预防性抗凝持续时间对全髋/膝关节置换术后静脉血栓形成的影响[J]. 中国临床药理学与治疗学，2023，28（11）：1269-1274.

LU K P，LIU C H，BI Y. Effect of prophylactic anticoagulation duration on venous thrombosis after total hip/knee arthroplasty[J]. Chin J Clin Pharmacol Ther，2023，28（11）：1269-1274.

MCDONALD S，PAGE M J，BERINGER K，et al. Pre-operative education for hip or knee replacement[J]. Cochrane Database Syst Rev，2014，2014（5）：CD003526.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction of pharmacogenomics-guided individualized medication list for elderly patients

4种常用中药注射剂临床抗肿瘤有效性的循证药学评价

循证药学思想在肿瘤科临床药学教学中的应用

循证药学方法在临床药师工作中的运用

临床药师基于循证方法对1例晚期肺癌脑转移患者的药学监护

Related Author

YI Zhanmiao

ZHAO Rongsheng

LI Ting

LIU Shuang

LI Xinya

WU Jingjing

JI Liwei

ZHANG Qingxia

Related Institution

Dept. of Pharmacy， Peking University Third Hospital

Drug Evaluation Center， Health Science Center， Peking University

Dept. of Pharmaceutical Management and Clinical Pharmacy， College of Pharmacy， Peking University

Dept. of Pharmacy/National Clinical Medical Research Center for Geriatrics， Beijing Hospital

Dept. of Pharmacy/National Clinical Medical Research Center for Geriatrics， Capital Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰